Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Shim
George Mason University, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Covenant Therapeutics, L.L.C.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The grant (named above) involves development of specific compounds for use in the treatment of COPD. One focus of this research involves derivatives of 4-MDM which has been the focus of similar research in Dr. Shim’s lab previously. Covenant Therapeutics has entered into an exclusive license agreement with the UVA Licensing and Ventures Group for 4-MDM. While the new (NIH) project will only test newly synthesized compounds, it is possible that some of these will fall inside the license agreement with Covenant. Thus, this project could effect the financial interest of Covenant Therapeutics, and, as an equity holder, the financial interests of Dr. Shim. As Dr. Shim is an investigator on this project, the UVA COI Committee determined that this was a financial conflict of interest as set out in 42 CFR Part 50.604 (f).
Discovery of New Anti-Inflammatory Agents to Treat COPD
Emphysematous chronic obstructive pulmonary disease (COPD) is an irreversible lung disease of increasing prevalence for which effective disease modifying therapy is not available. Based on these needs, we propose specific aims to design and synthesize new compounds that activate the LTA4H aminopeptidase activity as a target for treating COPD. We believe that our proposed work and expected outcomes will lead to new understandings of the conventional knowledge and therapeutic options associated with the biology of LTA4H enzyme and COPD.
Filed on November 07, 2016.
Tell us what you know about Michael Shim's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.